3 August 2014 in Nature Nanotechnology
28 February 2013 in Arthritis & Rheumatism
Objective: To examine the role of immune dysregulation in antibiotic‐refractory Lyme arthritis by comparing the phenotype, frequency, and function of CD4+ Teff cells and Treg cells in patients with antibiotic‐ responsive arthritis and patients with antibiotic‐refractory arthritis.Methods: Matched peripheral blood and synovial fluid samples from 15 patients with antibiotic‐responsive arthritis were compared with those from 16 patients with antibiotic‐refractory arthritis, using flow cytometry, suppression assays, and cytokine assays.Results: Critical differences between the 2 patient groups were observed in the synovial fluid CD4+CD25high population, a cell subset usually composed of FoxP3‐positive Treg cells. In patients with antibiotic‐refractory arthritis, this cell population often had fewer FoxP3‐positive cells and a greater frequency of FoxP3‐negative (Teff) cells compared with patients with antibiotic‐responsive arthritis. Moreover, the expression of glucocorticoid‐induced tumor necrosis factor receptor and OX40 on CD4+CD25high cells was significantly higher in the antibiotic‐refractory group. Suppression assays showed that CD4+CD25high cells in patients with antibiotic‐refractory arthritis did not effectively suppress proliferation of CD4+CD25− cells or secretion of interferon‐γ and tumor necrosis factor α, whereas those cells in patients with antibiotic‐responsive arthritis did suppress proliferation of CD4+CD25− cells and secretion of interferon‐γ and tumor necrosis factor α. Finally, in the antibiotic‐refractory group, higher ratios of CD25high FoxP3‐negative cells to CD25high FoxP3‐positive cells correlated directly with a longer duration of arthritis after antibiotic treatment.Conclusion: Patients with antibiotic‐refractory Lyme arthritis often have lower frequencies of Treg cells, higher expression of activation coreceptors, and less effective inhibition of proinflammatory cytokines. This suggests that immune responses in these patients are excessively amplified, leading to immune dysregulation and antibiotic‐refractory arthritis.
15 July 2014 in The Journal of Immunology
Immune-deficient mice, reconstituted with human stem cells, have been used to analyze human immune responses in vivo. Although they have been used to study immune responses to xenografts, allografts, and pathogens, there have not been models of autoimmune disease in which the mechanisms of the pathologic process can be analyzed. We have found that reconstituted “humanized” mice treated with anti–CTLA-4 Ab (ipilimumab) develop autoimmune disease characterized by hepatitis, adrenalitis, sialitis, anti-nuclear Abs, and weight loss. Induction of autoimmunity involved activation of T cells and cytokine production, and increased infiltration of APCs. When anti–CTLA-4 mAb–treated mice were cotreated with anti-CD3 mAb (teplizumab), hepatitis and anti-nuclear Abs were no longer seen and weight loss did not occur. The anti-CD3 blocked proliferation and activation of T cells, release of IFN-γ and TNF, macrophage infiltration, and release of IP-10 that was induced with anti–CTLA-4 mAb. We also found increased levels of T regulatory cells (CD25+CD127−) in the spleen and mesenteric lymph nodes in the mice treated with both Abs and greater constitutive phosphorylation of STAT5 in T regulatory cells in spleen cells compared with mice treated with anti–CTLA-4 mAb alone. We describe a model of human autoimmune disease in vivo. Humanized mice may be useful for understanding the mechanisms of biologics that are used in patients. Hepatitis, lymphadenopathy, and other inflammatory sequelae are adverse effects of ipilimumab treatment in humans, and this study may provide insights into this pathogenesis and the effects of immunologics on autoimmunity.
22 October 2009 in Genes & Immunity
18 December 2008 in Genes & Immunity
1 June 2007 in International Journal of Cancer
Interleukin‐7‐receptor‐signaling plays a pivotal role in T‐cell development and maintenance of T‐cell memory. We studied IL‐7Rα (CD127) expression in PBMCs obtained from patients with breast cancer and examined IL‐7 receptor‐mediated downstream effects defined by STAT5 phosphorylation (p‐STAT5). Reduced numbers of IL‐7Rα‐positive cells were identified in CD4+ T‐cells as well as in a CD8+ T‐cell subset defined by CD8α/α homodimer expression in patients with breast cancer. PBMCs obtained from healthy donors (n = 19) and from patients with breast cancer (n = 19) exhibited constitutive p‐STAT5 expression in the range of 0–6.4% in CD4+ T‐cells and 0–4% in CD8+ T‐cells. Stimulation with recombinant human IL‐7 for 15 min increased p‐STAT5 expression up to 36–97% in CD4+T‐cells and to 26–90% in CD8+T‐cells obtained from healthy control donors (n = 19). In contrast, PBMCs obtained from 13/19 patients with breast cancer did not respond to IL‐7 as defined by STAT5 phosphorylation, despite expression of IL‐7Rα on T‐lymphocytes. T‐cells were further characterized for IL‐ 2 and IFN‐γ production induced by PMA/Ionomycin. PBMCs from 9/19 patients with breast cancer showed decreased IL‐2 and IFN‐γ production combined with IL‐7‐signaling defects; PBMCs from 4 patients with breast cancer exhibited deficient IL‐7‐signaling, yet intact cytokine production. Reduced numbers of IL‐7Rα‐positive cells and nonresponsiveness to IL‐7, defined by lack of STAT5 phosphorylation, characterizes the immunological profile in T‐cells from patients with breast cancer.